New test could predict which fibroid patients benefit from drug treatment

Researchers have identified molecular markers that predict how uterine fibroid patients will respond to ulipristal acetate, a key treatment option. The finding could help clinicians avoid ineffective treatments and improve outcomes for the millions of women affected by fibroids, a condition costing the healthcare system billions annually.

Originaltitel: Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate